George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
“ Loads of tech rebounding, Netflix, Meta, Tesla Nvidia to name a few:”
These are huge multi billion dollar companies. Comparing a tiny unprofitable microcap to these companies is absolutely ridiculous.
There will be no significant rerate of SEE share price until interest rates turn and funds flow back into riskier growth equities.
As long as the company ensures it is executing through this down market and does it’s upmost to maintain or grow market share then the SP will take care of itself eventually…… but I doubt it will be in 2023.
I suggest you check again…….. and as for ‘moving the needle’ the stock price here went down shortly after SEE won the largest ever DMS contract. If you think contract wins are going to ‘move the needle’ in the current macro you are mistaken. Until the interest rate cycle turns SEE share price will struggle.
Thu, 22nd Dec 2022 07:02
RNS Number : 5959K
Seeing Machines Limited
22 December 2022
This announcement contains inside information
Seeing Machines Limited ("Seeing Machines" or the "Company")
22 December 2022
Seeing Machines appointed to deliver additional DMS OEM program
Seeing Machines Limited (AIM: SEE, "Seeing Machines" or the "Company"), the advanced computer vision technology company that designs AI-powered operator monitoring systems to improve transport safety, has been appointed by an existing Tier-1 customer to deliver its FOVIO Driver and Occupant Monitoring System (DMS/OMS) for an additional program with an existing large European-based global automotive group (OEM) customer.
This program, to be delivered via Seeing Machines' embedded Driver Monitoring Engine (FOVIO e-DME software library), is geared to lower integration cost and will substantially extend DMS and OMS reach across a broad range of vehicle models (including entry level vehicles), while addressing both regulatory requirements and in-cabin comfort and convenience oriented features. The program carries an initial lifetime value of US$32M (A$45M) and is scheduled to start production in 2024.
Seeing Machines continues to grow as an automotive technology leader in Driver and Occupant Monitoring Systems, having now won a total of 15 automotive programs spanning 10 individual OEMs, covering more than 160 distinct vehicle models. The cumulative initial lifetime value of all OEM programs that Seeing Machines has won to date now stands at US$321M (A$435M).
Nick DiFiore, SVP and GM Automotive commented:
"This is a great example of our existing Tier 1 and OEM relationships and cooperation leading to the increasingly extended reach of our technology across the global passenger vehicle landscape, which is not only driven by driver safety regulation but also an increasing demand for interior monitoring systems extending the comfort, convenience, and safety of all vehicle occupants."
The person responsible for this announcement is Paul McGlone, CEO.
ADAS is not DMS so this does not help OEM’s meet the upcoming regulations for monitoring the driver…….
https://www.primemovermag.com.au/high-stakes/
As others have said watch the KPI’s. SEE are confident enough to publicise those numbers to the market quarterly….. whilst competitors aren’t.
I couldn’t name any company that makes any of the multiple safety components in the car I drive. I don’t expect 99.9% of the population care. At the end of the day it’s a $10 chip.
Personally I hope the company focuses on execution and winning new business as the rest is just ego.
“( I for one really don't want to wait that long and will struggle to do so)”
So you wouldn’t be prepared to wait 5 years for a potential 20x return on investment? The vast majority would give their left kidney for that kind of return!
Really? It’s not ridiculous at all. No stock goes up continuously.
I will be holding this company until it gets taken over so it really does make no odds whether it’s 4p or 6p. No point in sitting and watching paper profits/losses go up and down if you don’t intend on selling the stock.
Didn’t they say in the last rns that the trial was continuing and that completion of 1a is by mid year? Just because they didn’t say what the dosage was doesn’t mean the trial stopped. If you look at the dosages from the previous cohorts it is pretty easy to work out what the next dosage would likely be.
The FUD on here and twitter has been designed to make people think it’s been delayed and it’s worked.
David, that is ridiculous. There have been 24 director purchases since the 1st of November. Do you truly believe that PM not buying informs the market of his lack of confidence executing the plan.
The 24 purchases by directors who also understand seeing machines strategic plan has done nothing to convince the market if the SP is anything to go by and a PM purchase will not do anything to convince it either.
The company needs to build a significant auto order book indicating a 40% market share, as well as prove its fleet and aviation verticals to convince a difficult market to get behind the company.
The $32m dollar SEE win from late December 22 was for 2024 production so I think Paul has a good understanding of what is happening right now.
“ The program carries an initial lifetime value of US$32M (A$45M) and is scheduled to start production in 2024.”
“ It needed an interview with AS,who is excellent at bringing it down to normal level, explaining what the results meant.But not to be.almoat like they aren't interested in retail investors...who would have thought”
There was an interview on the 17th of January which quite clearly outlined the implications of the data for investors, as did the rns on the 17th Jan……… yet many people didn’t want to believe the words in the rns OR the words in that interview. All science day did was provide the numbers that backed up the rns and interview from the 17th Jan.